Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 739 matching trials from the live ClinicalTrials.gov search.
Filters: "fallopian tube" Condition: Ovarian Cancer Clear all
Not yet recruiting Phase 2 Interventional

Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin

NCT07815704
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer, High Grade Serous Adenocarcinoma of Ovary
Interventions
Standard of Care + atorvastatin, Standard of Care (SOC)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 13, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00429793
View directory record Official record
Conditions
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
temsirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 13, 2026, 5:39 PM EDT
Recruiting Phase 1 Interventional

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

NCT06856499
View directory record Official record
Conditions
Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Cirtuvivint, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 13, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

NCT00993655
View directory record Official record
Conditions
Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
carboplatin, cisplatin, paclitaxel
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older · Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Springfield, Missouri • Oklahoma City, Oklahoma • Providence, Rhode Island + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 13, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer

NCT01031381
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
RAD001, bevacizumab
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 13, 2026, 5:39 PM EDT
Withdrawn Phase 1 Interventional

Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02050009
View directory record Official record
Conditions
Ovarian Papillary Serous Carcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer
Interventions
metformin hydrochloride, carboplatin, paclitaxel, laboratory biomarker analysis
Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 13, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01666444
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
136
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 13, 2026, 5:39 PM EDT
Withdrawn Phase 1 Interventional

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

NCT06161493
View directory record Official record
Conditions
Ovarian Cancer, Recurrent Solid Tumors
Interventions
ZEN003694, Niraparib
Drug
Lead sponsor
Haider Mahdi
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 13, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00066456
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
3-Dimensional Conformal Radiation Therapy, Chemosensitization/Potentiation Therapy, Docetaxel
Radiation · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 13, 2026, 5:39 PM EDT
Completed Early Phase 1 Interventional

Why do Oral Contraceptives Prevent Ovarian Cancer?

NCT02155777
View directory record Official record
Conditions
Ovarian Cancer Risk, Risk-reducing Surgery, Fallopian Tube Fimbriae, Ovarian Cortical Inclusion Cysts
Interventions
OrthoNovum 1/35
Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 45 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 13, 2026, 5:39 PM EDT
Recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions
Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
479
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 5:39 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

NCT04616534
View directory record Official record
Conditions
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Elimusertib, Gemcitabine
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 13, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Results available

Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

NCT02903771
View directory record Official record
Conditions
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions
Part A: Dose Escalation of Cantrixil, Part B: Expansion Cohort of Cantrixil
Drug
Lead sponsor
Kazia Therapeutics Limited
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Oklahoma City, Oklahoma • Providence, Rhode Island • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 13, 2026, 5:39 PM EDT
Terminated Phase 1 Interventional

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

NCT04244552
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Acral Lentiginous Melanoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Melanoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer
Interventions
ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
Biological · Drug
Lead sponsor
Atreca, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 13, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy

NCT04415944
View directory record Official record
Conditions
Ovarian Epithelial Cancer Stage I, Ovarian Epithelial Cancer Stage II, Ovarian Epithelial Cancer Stage III, Stage I Fallopian Tube Cancer, Stage II Fallopian Tube Cancer, Stage III Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions
Second look laparoscopy reassessment surgery (SLLRS), HIPEC with Carboplatin, FACT-O Quality of Life Questionnaire
Procedure · Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 13, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Results available

Tivozanib As Maintenance Therapy In GYN

NCT01972516
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Tivozanib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 13, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02901899
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Guadecitabine, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 13, 2026, 5:39 PM EDT
Not listed No phase listed Observational

Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer

NCT00499512
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
4
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 13, 2026, 5:39 PM EDT
Terminated No phase listed Observational

Natera Ovarian Cancer Detection Assay

NCT03485651
View directory record Official record
Conditions
Adnexal Mass
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 13, 2026, 5:39 PM EDT
Not listed No phase listed Observational

International Ovarian Tumour Analysis (IOTA) Phase 5

NCT01698632
View directory record Official record
Conditions
Adnexal Masses, Ovarian Cysts, Ovarian Tumors
Interventions
Not listed
Lead sponsor
KU Leuven
Other
Eligibility
18 Years and older · Female only
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 13, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00003967
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
etoposide, topotecan hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Iowa City, Iowa • Baltimore, Maryland • Camden, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 13, 2026, 5:39 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00565851
View directory record Official record
Conditions
Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
Interventions
Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2028
U.S. locations
680
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 421 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 13, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT00003345
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, irinotecan hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 13, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00066729
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
NY-ESO-1 peptide vaccine
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 13, 2026, 5:39 PM EDT